公开(公告)号：JP2002338566A

公开(公告)日：2002-11-27

申请号：JP2002106212

申请日：2002-04-09

Applicant: SERVIER LAB

Inventor： PEGLION JEAN-LOUIS ,  POITEVIN CHRISTOPHE ,  VILAINE JEAN-PAUL ,  VILLENEUVE NICOLE ,  BOURGUIGNON MARIE PIERRE ,  THOLLON CATHERINE

IPC: C07D417/14 ,  A61K31/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61K31/551 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P43/00 ,  C07D209/08 ,  C07D211/00 ,  C07D211/26 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/06 ,  C07D471/04 ,  C07D491/04

Abstract: PROBLEM TO BE SOLVED: To provide a medicine useful for the treatment of a disease or a pathological state which is known that the disorder of endothelial function is the cause of the disease and/or the mechanism of worsening the disease because the medicine can limit the disorder of the endothelial function or the reduction of ability for utilizing the blood vessel. SOLUTION: The compound represented by formula (I) [wherein, V is a single bond or the like; M is a single bond or the like; A and E are each a nitrogen atom or the like; R3 is an aryl or a heteroaryl A group which may be substituted as necessary; Y is an aryloxy which may be substituted as necessary or the like], the isomer, the hydrate, the solvate or the addition salt with a pharmaceutically acceptable acid are provided. The pharmaceutical composition containing the compound is also provided.

公开(公告)号：WO2015015102A3

公开(公告)日：2015-12-03

申请号：PCT/FR2014051944

申请日：2014-07-28

Applicant: SERVIER LAB ,  SHANGHAI INST PHARM INDUSTRY

Inventor： SHAN HANBIN ,  SHEN YUHUI ,  LUO YING ,  LETELLIER PHILIPPE ,  LYNCH MICHAEL

IPC: C07C303/32 ,  C07C233/18

CPC classification number: C07C309/35 ,  C07C231/12 ,  C07C233/18 ,  C07C303/22 ,  C07C309/29

Abstract: Novel complexes of agomelatine and sulphonic acids of formula (I). Drugs.

Abstract translation: 式（I）的阿维菌素和磺酸的新型络合物。 药品。

公开(公告)号：WO2015082848A3

公开(公告)日：2015-07-30

申请号：PCT/FR2014053158

申请日：2014-12-04

Applicant: SERVIER LAB

Inventor： BRIERE JEAN-FRANÇOIS ,  LEBEUF RAPHAËL ,  LEVACHER VINCENT ,  HARDOUIN CHRISTOPHE ,  LECOUVE JEAN-PIERRE

IPC: C07C47/575 ,  C07C309/74

CPC classification number: C07C309/73 ,  C07C45/64 ,  C07C309/66 ,  C07C47/575

Abstract: The invention relates to a method for the industrial synthesis of the compound of formula (I).

Abstract translation: 本发明涉及用于工业合成式（I）化合物的方法。

公开(公告)号：WO2013117869A3

公开(公告)日：2013-11-14

申请号：PCT/FR2013050265

申请日：2013-02-08

Applicant: SERVIER LAB

Inventor： PEDRAGOSA MOREAU SANDRINE ,  LEFOULON FRANCOIS

IPC: C12P7/40 ,  C07C62/34 ,  C07C69/753 ,  C07C213/08 ,  C07C217/58 ,  C07D223/16 ,  C12P7/62 ,  C12P41/00

CPC classification number: C12P17/10 ,  C07B2200/07 ,  C07C51/08 ,  C07C67/08 ,  C07C213/02 ,  C07C231/02 ,  C07C2602/06 ,  C07D223/16 ,  C12P7/40 ,  C12P7/62 ,  C12P13/001 ,  C12P41/005 ,  C12Y301/01 ,  Y02P20/52 ,  C07C62/34 ,  C07C69/757 ,  C07C217/74 ,  C07C235/40

Abstract: The invention relates to a method for enzymatically synthesizing the compound of formula (I), where R1 is a hydrogen atom or an alkyl group. The invention can be used in the synthesis of ivrabadine and the pharmaceutically acceptable acid addition salts thereof.

Abstract translation: 本发明涉及一种用于酶法合成式（I）化合物的方法，其中R1是氢原子或烷基。 本发明可用于合成ivrabadine及其药学上可接受的酸加成盐。

公开(公告)号：WO2011070253A8

公开(公告)日：2012-08-02

申请号：PCT/FR2010000823

申请日：2010-12-08

Applicant: SERVIER LAB ,  CASARA PATRICK ,  CHOLLET ANNE-MARIE ,  DHAINAUT ALAIN ,  HENLIN JEAN-MICHEL ,  LESTAGE PIERRE ,  PANAYI FANY

Inventor： CASARA PATRICK ,  CHOLLET ANNE-MARIE ,  DHAINAUT ALAIN ,  HENLIN JEAN-MICHEL ,  LESTAGE PIERRE ,  PANAYI FANY

IPC: C07D209/52 ,  A61K31/403 ,  A61P25/00

CPC classification number: C07D209/52

Abstract: The invention relates to the compounds of formula (I), where: ALK is an alkylene chain, and W is a grouping of formula (II) or formula (III), where R and R' are as defined in the description. The invention can be used as a drug.

Abstract translation: 本发明涉及式（I）化合物，其中：ALK是亚烷基链，W是式（II）或式（III）的基团，其中R和R'如说明书中所定义。 本发明可用作药物。

公开(公告)号：WO2010007253A3

公开(公告)日：2010-03-25

申请号：PCT/FR2009000870

申请日：2009-07-16

Applicant: SERVIER LAB ,  CENTRE NAT RECH SCIENT ,  UNIV CLAUDE BERNARD LYON ,  PEGLION JEAN-LOUIS ,  BAUDOIN OLIVIER ,  AUDIC NICOLAS ,  CHAUMONTET MANON ,  PICCARDI RICCARDO

Inventor： PEGLION JEAN-LOUIS ,  BAUDOIN OLIVIER ,  AUDIC NICOLAS ,  CHAUMONTET MANON ,  PICCARDI RICCARDO

IPC: C07B37/10 ,  C07C51/38 ,  C07C62/34 ,  C07C67/317 ,  C07C67/32 ,  C07C69/753 ,  C07C69/757 ,  C07C69/76 ,  C07C213/02 ,  C07C213/10 ,  C07C217/58 ,  C07C231/02 ,  C07C235/40 ,  C07C253/30 ,  C07C255/47

CPC classification number: C07C51/38 ,  C07B37/10 ,  C07B2200/07 ,  C07C62/34 ,  C07C67/317 ,  C07C67/32 ,  C07C69/753 ,  C07C69/757 ,  C07C253/30 ,  C07C2602/22 ,  C07D223/16 ,  C07F7/1856 ,  C07C69/76 ,  C07C255/47

Abstract: A method for preparing the compounds of formula (IV): in which R1, R2, R3 and R4, which may be identical or different, are each a hydrogen atom, a linear or branched (C1-C6) alkyl group, a linear or branched (C1-C6) alkoxy group, a fluorine or chlorine atom, a protected amino group, a protected hydroxyl group, an alkoxycarbonyl group in which the alkoxy group is linear or branched (C1-C6), or a CF3 group, or R1=R4=H and R2 and R3 form, together with the carbon atoms which bear them, a 1,3-dioxolane group, R5 is a saturated or unsaturated, linear or branched (C1-C6) alkyl group, a linear or branched (C1-C6) hydroxyalkyl group in which the hydroxyl function is protected, or a CO2R7 group in which R7 is a linear or branched (C1-C6) alkyl group, and R6 is a cyano group or a CO2R8 group in which R8 is a linear or branched (C1-C6) alkyl group. Use in the synthesis of ivabradine, of addition salts thereof with a pharmaceutically acceptable acid, and of hydrates thereof.

Abstract translation: 制备式（IV）化合物的方法：其中R1，R2，R3和R4可以相同或不同，各自为氢原子，直链或支链（C1-C6）烷基，直链或支链 支链的（C1-C6）烷氧基，氟或氯原子，被保护的氨基，被保护的羟基，其中烷氧基为直链或支链的烷氧基羰基（C1-C6），或CF3基团，或R1 = R 4 = H且R 2和R 3与带有它们的碳原子一起形成1,3-二氧戊环基团，R 5为饱和或不饱和的直链或支链（C 1 -C 6）烷基，直链或支链 C1-C6）羟烷基或其中R7为直链或支链（C1-C6）烷基，且R6为氰基或CO2R8基团的CO2R7基团，其中R8为直链或支链 或支链（C1-C6）烷基。 用于合成伊伐布雷定，其与可药用酸的加成盐及其水合物的合成。

公开(公告)号：WO2009066035A3

公开(公告)日：2009-08-27

申请号：PCT/FR2008001261

申请日：2008-09-10

Applicant: SERVIER LAB ,  VERBEUREN TONY ,  SANSILVESTRI-MOREL PATRICIA ,  RUPIN ALAIN ,  VALLEZ MARIE-ODILE ,  FRATACCI MARIE-DOMINIQUE ,  LREOND LAURENCE ,  LAVIELLE GILBERT

Inventor： VERBEUREN TONY ,  SANSILVESTRI-MOREL PATRICIA ,  RUPIN ALAIN ,  VALLEZ MARIE-ODILE ,  FRATACCI MARIE-DOMINIQUE ,  LREOND LAURENCE ,  LAVIELLE GILBERT

IPC: C07C311/20 ,  A61K31/18 ,  A61K31/404 ,  C07D209/42

CPC classification number: C07D209/42 ,  A61K31/18 ,  A61K31/404 ,  A61K45/06 ,  C07C311/20 ,  A61K2300/00

Abstract: Combination of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also pharmaceutical compositions containing same. Medicaments

Abstract translation: 抗动脉粥样硬化血栓形成和血管紧张素转化酶抑制剂（ACEI）的组合，以及含有其的药物组合物。 药品

公开(公告)号：WO2008049997A8

公开(公告)日：2009-05-22

申请号：PCT/FR2007001708

申请日：2007-10-17

Applicant: SERVIER LAB ,  MARCHAND PASCAL ,  BABONNEAU VINCENT ,  PIESSARD SYLVIE ,  DUFLOS MURIEL ,  BOUTIN JEAN ALBERT ,  AUDINOT VALERIE ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI

Inventor： MARCHAND PASCAL ,  BABONNEAU VINCENT ,  PIESSARD SYLVIE ,  DUFLOS MURIEL ,  BOUTIN JEAN ALBERT ,  AUDINOT VALERIE ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI

IPC: C07D209/32 ,  A61K31/4045

CPC classification number: C07D209/14

Abstract: Compounds of formula (I): in which: R1 is an alkyl, cycloalkyl or cycloalkylalkyl group, R2 and R3 form, together with the nitrogen atom which bears them, a heterocycle comprising from 5 to 8 ring members, and n is 2 to 6; medicaments.

Abstract translation: 式（I）化合物：其中：R1是烷基，环烷基或环烷基烷基，R2和R3与带有它们的氮原子一起形成包含5至8个环成员的杂环，n是2至6 ; 药物。

公开(公告)号：WO2008071869A2

公开(公告)日：2008-06-19

申请号：PCT/FR2007001925

申请日：2007-11-23

Applicant: SERVIER LAB ,  SPEDDING MICHAEL ,  MOCAER ELISABETH

Inventor： SPEDDING MICHAEL ,  MOCAER ELISABETH

CPC classification number: A61K31/165

Abstract: The invention relates to the use of agomelatine or N-[2-(7-methoxy-1-naphtyl)ethyl]acetamide in order to obtain drugs intended for the treatment of periventricular leukomalacia.

Abstract translation: 本发明涉及阿戈美拉汀或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺以获得用于治疗脑室周围白质软化症的药物的用途。

公开(公告)号：WO2008049996A3

公开(公告)日：2008-06-19

申请号：PCT/FR2007001707

申请日：2007-10-17

Applicant: SERVIER LAB ,  MARCHAND PASCAL ,  BABONNEAU VINCENT ,  PIESSARD SYLVIE ,  DUFLOS MURIEL ,  BOUTIN JEAN ALBERT ,  AUDINOT VALERIE ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI

Inventor： MARCHAND PASCAL ,  BABONNEAU VINCENT ,  PIESSARD SYLVIE ,  DUFLOS MURIEL ,  BOUTIN JEAN ALBERT ,  AUDINOT VALERIE ,  DELAGRANGE PHILIPPE ,  CAIGNARD DANIEL-HENRI

IPC: C07D209/42 ,  A61K31/404 ,  A61P1/00 ,  A61P9/00 ,  A61P15/00 ,  A61P25/00 ,  A61P35/00

CPC classification number: C07D209/42

Abstract: The invention relates to compounds of formula (I), in which: R is an alkyl, cycloalkyl or cycloalkylalkyl group, R is a linear or branched (C 1 -C 6 ) alkyl group, and n is 1 to 6, and to the use thereof for the treatment of disorders in the melatoninergic system, such as sleep disorders, stress, anxiety, cardiovascular pathologies, etc..

Abstract translation: 本发明涉及式（I）化合物，其中：R是烷基，环烷基或环烷基烷基，R是直链或支链（C 1 -C 6 - ）烷基，n为1至6，以及其用于治疗褪黑激素系统中的疾病的用途，例如睡眠障碍，应激，焦虑，心血管病变等。